Literature DB >> 22434137

Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo.

Friederike Herbst1, Claudia R Ball, Francesca Tuorto, Ali Nowrouzi, Wei Wang, Oksana Zavidij, Sebastian M Dieter, Sylvia Fessler, Franciscus van der Hoeven, Ulrich Kloz, Frank Lyko, Manfred Schmidt, Christof von Kalle, Hanno Glimm.   

Abstract

Lentiviral vectors (LV) are widely used to stably transfer genes into target cells investigating or treating gene functions. In addition, gene transfer into early murine embryos may be improved to efficiently generate transgenic mice. We applied lentiviral gene transfer to generate a mouse model transgenic for SET binding protein-1 (Setbp1) and enhanced green fluorescent protein (eGFP). Neither transgenic founders nor their vector-positive offspring transcribed or expressed the transgenes. Bisulfite sequencing of the internal spleen focus-forming virus (SFFV) promoter demonstrated extensive methylation of all analyzed CpGs in the transgenic mice. To analyze the impact of Setbp1 on epigenetic silencing, embryonic stem cells (ESC) were differentiated into cardiomyocytes (CM) in vitro. In contrast to human promoters in LV, virally derived promoter sequences were strongly methylated during differentiation, independent of the transgene. Moreover, the commonly used SFFV promoter (SFFVp) was highly methylated with remarkable strength and frequency during hematopoietic differentiation in vivo in LV but less in γ-retroviral (γ-RV) backbones. In summary, we conclude that LV using an internal SFFVp are not suitable to generate transgenic mice or perform constitutive expression studies in differentiating cells. Choosing the appropriate promoter is also crucial to allow stable transgene expression in clinical gene therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434137      PMCID: PMC3345972          DOI: 10.1038/mt.2012.46

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  45 in total

1.  Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter.

Authors:  C Brendel; U Müller-Kuller; S Schultze-Strasser; S Stein; L Chen-Wichmann; A Krattenmacher; H Kunkel; A Dillmann; M N Antoniou; M Grez
Journal:  Gene Ther       Date:  2011-11-10       Impact factor: 5.250

2.  Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing.

Authors:  Anna Paruzynski; Anne Arens; Richard Gabriel; Cynthia C Bartholomae; Simone Scholz; Wei Wang; Stephan Wolf; Hanno Glimm; Manfred Schmidt; Christof von Kalle
Journal:  Nat Protoc       Date:  2010-07-08       Impact factor: 13.491

Review 3.  Gene therapy for adenosine deaminase deficiency.

Authors:  Barbara Cappelli; Alessandro Aiuti
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

4.  A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors.

Authors:  Fang Zhang; Amy R Frost; Mike P Blundell; Olivia Bales; Michael N Antoniou; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-06-29       Impact factor: 11.454

5.  The dinucleotide CG as a genomic signalling module.

Authors:  Adrian Bird
Journal:  J Mol Biol       Date:  2011-02-03       Impact factor: 5.469

6.  Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice.

Authors:  C P Kalberer; R Pawliuk; S Imren; T Bachelot; K J Takekoshi; M Fabry; C J Eaves; I M London; R K Humphries; P Leboulch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Lentiviral transgenesis.

Authors:  Terunaga Nakagawa; Casper C Hoogenraad
Journal:  Methods Mol Biol       Date:  2011

8.  Stem-cell gene therapy for the Wiskott-Aldrich syndrome.

Authors:  Kaan Boztug; Manfred Schmidt; Adrian Schwarzer; Pinaki P Banerjee; Inés Avedillo Díez; Ricardo A Dewey; Marie Böhm; Ali Nowrouzi; Claudia R Ball; Hanno Glimm; Sonja Naundorf; Klaus Kühlcke; Rainer Blasczyk; Irina Kondratenko; László Maródi; Jordan S Orange; Christof von Kalle; Christoph Klein
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

9.  Efficacy of gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Julia Hauer; Annick Lim; Capucine Picard; Gary P Wang; Charles C Berry; Chantal Martinache; Frédéric Rieux-Laucat; Sylvain Latour; Bernd H Belohradsky; Lily Leiva; Ricardo Sorensen; Marianne Debré; Jean Laurent Casanova; Stephane Blanche; Anne Durandy; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2010-07-22       Impact factor: 91.245

10.  Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET.

Authors:  Toshiyuki Matsui; Danny Leung; Hiroki Miyashita; Irina A Maksakova; Hitoshi Miyachi; Hiroshi Kimura; Makoto Tachibana; Matthew C Lorincz; Yoichi Shinkai
Journal:  Nature       Date:  2010-02-17       Impact factor: 49.962

View more
  44 in total

Review 1.  Gene therapy using stem cells.

Authors:  Erin R Burnight; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-13       Impact factor: 6.915

Review 2.  Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Authors:  Catalina Méndez; Chantelle L Ahlenstiel; Anthony D Kelleher
Journal:  World J Virol       Date:  2015-08-12

3.  Engraftment potential of adipose tissue-derived human mesenchymal stem cells after transplantation in the fetal rabbit.

Authors:  Itziar Martínez-González; Rafael Moreno; Jordi Petriz; Eduard Gratacós; Josep M Aran
Journal:  Stem Cells Dev       Date:  2012-07-31       Impact factor: 3.272

4.  Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Authors:  D Hoffmann; J W Schott; F K Geis; L Lange; F-J Müller; D Lenz; D Zychlinski; D Steinemann; M Morgan; T Moritz; A Schambach
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

5.  A GLIS3-CD133-WNT-signaling axis regulates the self-renewal of adult murine pancreatic progenitor-like cells in colonies and organoids.

Authors:  Jacob R Tremblay; Kassandra Lopez; Hsun Teresa Ku
Journal:  J Biol Chem       Date:  2019-09-18       Impact factor: 5.157

6.  Efficient and Reproducible Multigene Expression after Single-Step Transfection Using Improved BAC Transgenesis and Engineering Toolkit.

Authors:  Binhui Zhao; Pankaj Chaturvedi; David L Zimmerman; Andrew S Belmont
Journal:  ACS Synth Biol       Date:  2020-04-13       Impact factor: 5.110

7.  Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.

Authors:  Erik Pittermann; Nico Lachmann; Glenn MacLean; Stephan Emmrich; Mania Ackermann; Gudrun Göhring; Brigitte Schlegelberger; Karl Welte; Axel Schambach; Dirk Heckl; Stuart H Orkin; Tobias Cantz; Jan-Henning Klusmann
Journal:  Blood Adv       Date:  2017-06-02

8.  Next-generation libraries for robust RNA interference-based genome-wide screens.

Authors:  Martin Kampmann; Max A Horlbeck; Yuwen Chen; Jordan C Tsai; Michael C Bassik; Luke A Gilbert; Jacqueline E Villalta; S Chul Kwon; Hyeshik Chang; V Narry Kim; Jonathan S Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

9.  Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Authors:  Michael T Eadon; Heather E Wheeler; Amy L Stark; Xu Zhang; Erika L Moen; Shannon M Delaney; Hae Kyung Im; Patrick N Cunningham; Wei Zhang; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2013-05-29       Impact factor: 6.150

10.  Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Authors:  E Bôle-Richard; C Gamonet; J-M Certoux; I Idirene; F Larosa; E Deconinck; A-M Mosseley; P Tiberghien; C Borg; C Ferrand; M Deschamps
Journal:  Gene Ther       Date:  2016-05-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.